Skip to application
All calculators and tools

Preparation. Administration. Evidence.

IV Dilution &
Medication Reference

Search 255 medications, read preserved historical references, and inspect separately reviewed preparation statements. Full monograph updates remain pending.

Version 6.4Release date 2026-11-04For healthcare professionals
Back to resultsA-Z list

Medication reference

Thiamine

Monograph awaiting updateThis monograph will be updated in the future.

Jump to a section

Historical source. Current clinical review is incomplete. This monograph will be updated in the future.

Thiamine (opens in a new tab)Original source URL: https://globalrph.com/dilution/thiamine/ | Retrieved 2026-11-04

Source dates, location and integrity

This historical article is separate from the reviewed claim cards. Product formulations and source dates may differ.

Original source URL
https://globalrph.com/dilution/thiamine/ (opens in a new tab)
Source date
Not established in the retrieved source
Retrieved
2026-11-04T19:49:56.640884+00:00
Source location
div.post-content
Packaged content SHA-256
e3a9e05ec80c102e0f6c735b613dec40facda2f4ce9f6d846a2dcac745520996
Original response SHA-256
86b020a04a6bdf42d4368fc4df5ac80af9238c511b1f1f6772aebc017a643db5
Source body SHA-256
cdf5a2b96d93db8e57158b888742babbfbdf2e84ac5001e776df37019e78cf3a

Thiamine Hydrochloride

The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents

D5W, NS , Dextrose-saline combinations, LR, D5LR

Standard Dilution [Amount of drug] [Infusion volume] [Infusion rate]

[100 mg] [50 - 100 ml] [15 - 30 minutes]
[250 mg] [100 ml] [30 minutes]
[500 mg] [250 ml] [30-60 minutes]
Wernicke's encephalopathy (treatment):

1] Package insert: in the treatment of Wernicke-Korsakoff syndrome, thiamine hydrochloride has been administered IV in an initial dose of 100 mg, followed by IM doses of 50 to 100 mg daily until the patient is consuming a regular, balanced diet.

2] High dose regimen: 500 mg IV three times per day x 3 days. If patient responds to therapy, continue with 250 mg IM/IV once daily x 5 days or until clinical improvement.

Source: Thomson AD, Cook CC, Touquet R, et al, "The Royal College of Physicians Report on Alcohol: Guidelines for Managing Wernicke's Encephalopathy in the Accident and Emergency Department," Alcohol Alcohol, 2002, 37(6):513-21.

Review warnings below.

Stability / Miscellaneous

Stability: 24 hours RT or Ref.

CLINICAL PHARMACOLOGY: The water soluble vitamins are widely distributed in both plants and animals. They are absorbed in man by both diffusion and active transport mechanisms. These vitamins are structurally diverse (derivatives of sugar, pyridine, purines, pyrimidine, organic acid complexes and nucleotide complex) and act as coenzymes, as oxidation-reduction agents, possibly as mitochondrial agents. Metabolism is rapid, and the excess is excreted in the urine. Thiamine is distributed in all tissues. The highest concentrations occur in liver, brain, kidney and heart. When thiamine intake is greatly in excess of need, tissue stores increase two to three times. If intake is insufficient, tissues become depleted of their vitamin content. Absorption of thiamine following IM administration is rapid and complete. Thiamine combines with adenosine triphosphate (ATP) to form thiamine pyrophosphate, also known as cocarboxylase, a coenzyme. Its role in carbohydrate metabolism is the decarboxylation of pyruvic acid in the blood and -ketoacids to acetaldehyde and carbon dioxide. Increased levels of pyruvic acid in the blood indicate vitamin B1 deficiency. The requirement for thiamine is greater when the carbohydrate content of the diet is raised. Body depletion of vitamin B1 can occur after approximately three weeks of total absence of thiamine in the diet.

INDICATIONS AND USAGE: Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given.

WARNINGS:
WARNING: This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration. Serious hypersensitivity/anaphylactic reactions can occur, especially after repeated administration. Deaths have resulted from IV or IM administration of thiamine (see package insert for ADVERSE REACTIONS). Routine testing for hypersensitivity, in many cases, may not detect hypersensitivity. Nevertheless, a skin test should be performed on patients who are suspected of drug allergies or previous reactions to thiamine, and any positive responders should not receive thiamine by injection. If hypersensitivity to thiamine is suspected (based on history of drug allergy or occurrence of adverse reactions after thiamine administration), administer one-hundredth of the dose intradermally and observe for 30 minutes. If no reaction occurs, full dose can be given; the patient should be observed for at least 30 minutes after injection. Be prepared to treat anaphylactic reactions regardless of the precautions taken. Treatment of anaphylactic reactions includes maintaining a patent airway and the use of epinephrine, oxygen, vasopressors, steroids and antihistamines.

DOSAGE AND ADMINISTRATION:
"Wet" beriberi with myocardial failure must be treated as an emergency cardiac condition, and thiamine must be administered slowly by the IV route in this situation (see WARNINGS). In the treatment of beriberi, 10 to 20 mg of thiamine hydrochloride are given IM three times daily for as long as two weeks. (See WARNINGS regarding repeated injection of thiamine.) An oral therapeutic multivitamin preparation containing 5 to 10 mg thiamine, administered daily for one month, is recommended to achieve body tissue saturation. Infantile beriberi that is mild may respond to oral therapy, but if collapse occurs, doses of 25 mg may cautiously be given IV. Poor dietary habits should be corrected and an abundant and well-balanced dietary intake should be prescribed. Patients with neuritis of pregnancy in whom vomiting is severe enough to preclude adequate oral therapy should receive 5 to 10 mg of thiamine hydrochloride IM daily. In the treatment of Wernicke-Korsakoff syndrome, thiamine hydrochloride has been administered IV in an initial dose of 100 mg, followed by IM doses of 50 to 100 mg daily until the patient is consuming a regular, balanced diet. (See WARNINGS regarding repeated injections of thiamine.) Patients with marginal thiamine status to whom dextrose is being administered should receive 100 mg thiamine hydrochloride in each of the first few liters of IV fluid to avoid precipitating heart failure. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED: Product NDC Thiamine No. No. HCl/mL Volume 1302 63323-013-02 100 mg 2 mL 2 mL size is a multiple dose vial, packaged 25 vials per tray. Store at 20° to 25°C (68° to 77°F)
[see USP Controlled Room Temperature]. PROTECT FROM LIGHT. Use only if solution is clear and seal intact.

Reference(s)

Package Insert: Abraxis Pharmaceutical Products. Schaumburg, IL 60173. Revised: July 2006.

Open this historical article on its own

Product identifiers and clinical review status

This monograph will be updated in the future. Historical material is available where present in the original sources; full current exact-product and claim-level review remains pending.

Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.

What remains to be completed
  • Retrievable exact-product SPL XML with version, revision, retrieval date and reproducible hash
  • Clinically reviewed, individually identified statements with two exact source mappings
  • Exact formulation, strength, container, manufacturer/labeler, application and NDC reconciliation
  • Renal-function methods and dialysis/CRRT modality review where applicable
  • Mechanism provenance, clinical source disagreements and full medication-specific safety reconciliation

Supplemental historical fields

Restored-data provenance and review notes

Source release: 2026-08-31. Current clinical review is incomplete. Original uses of current, verified, or normalized describe the historical source. They do not inherit the status of separately reviewed statements. Product formulations and source dates can differ.

Current review annotations for historical renal, dialysis, mechanism, and product fieldsSeparate renal reference: Open Renal Dosing Master (opens in a new tab)
Renal
Status
not_locally_normalized
Original classification
current_label_review_required
Entries
    General note
    Preserve the source-specific renal-function basis. An indexed CrCl table is not interchangeable with unindexed CrCl or eGFR. Generic advice to check a method does not identify the equation for a dose row.
    Dialysis
    Status
    no_local_structured_regimen
    Entries
      General note
      Named modality alone does not establish applicability. CRRT subtype, effluent rate, residual renal function, timing and interruptions require review. Historical absence is not evidence that no guidance exists.
      Mechanisms
      • Source kind
        first_look
        Local pointer
        /mechanism
        Original level
        drug_specific
        Provenance classification
        historical_drug_specific_uncorroborated
        Label derived verified
        false
        Independently corroborated
        false
        Exact label section
        Not recorded
        Original source note
        Not recorded
        Review status
        historical_unverified
        Note
        Drug-specific wording in the old file is not proof of independent corroboration or an exact label locator. Consult separately published current mechanism claims where present.
      Future update
      Status
      pending_review
      Message
      This monograph will be updated in the future as current exact-product and claim-level review is completed.
      Source unavailable
      false
      Reason
      The historical content is restored; comprehensive contemporary verification remains incomplete.
      Historical first look: uses, mechanism, dosing context, and administration

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      thiamine
      Source IDH51-8166A253FAF0620DEA076248
      Generic name
      Thiamine
      Source IDH51-C692A08A06CD38DA8B02B3CE
      Class
      Toxicology and reversal
      Source IDH51-C2071EA8997168D530736CA3
      Subclass
      Vitamin
      Source IDH51-5FA9C4C6EFFDE10BC2B088F2
      Primary uses
      1. Suspected Wernicke encephalopathy
        Source IDH51-B8EB988511761E1C6FEC9F86
      2. Thiamine deficiency
        Source IDH51-57ECC252549A0894D66D6B96
      3. Refeeding-risk support
        Source IDH51-17B7EE7CBD901C652486B618
      Mechanism
      Provides thiamine pyrophosphate cofactor for oxidative carbohydrate metabolism.
      Source IDH51-9E031FDBD25F209C1D7DAB03
      Mechanism level
      drug_specific
      Source IDH51-BF7FB169DFDEDE01098CE710
      Basic dosing orientation
      Adult / Pediatric | Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation | Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation | Patient- and indication-specific | See current package insert | IV push
      Source IDH51-94473BF6E50647D829EA5210
      Administration orientation
      Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes; 100 mg/mL; dilute for high-dose therapy; Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes
      Source IDH51-20D3AA8CE316B101656E1C0D
      Renal and population orientation
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-FDB471785AE6A34B49F0BD9F
      Key safety orientation
      1. Rare anaphylaxis and hypotension.
        Source IDH51-82657F6F158EA0CCD79FB7FE
      Coverage path
      structured_local_snapshot
      Source IDH51-943BADBE5714304583F0E734
      Coverage path label
      Structured GlobalRPh route snapshot
      Source IDH51-26B5C78ED58699B73A5F55AD
      Legacy title
      Thiamine
      Source IDH51-D0ABC342C9F73568BED848A2
      Review note
      First-look orientation only. Verify indication, patient population, weight basis, organ function, exact IV product, dose, concentration, compatibility, rate, and current labeling before use.
      Source IDH51-F037ABAD4E883DCC6756EF4C
      Search text
      Thiamine Toxicology and reversal Vitamin Suspected Wernicke encephalopathy Thiamine deficiency Refeeding-risk support Provides thiamine pyrophosphate cofactor for oxidative carbohydrate metabolism. Adult / Pediatric | Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation | Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation | Patient- and indication-specific | See current package insert | IV push Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes; 100 mg/mL; dilute for high-dose therapy; Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes Renal dosing status has not been locally normalized; use the current package insert before ordering or administration. Rare anaphylaxis and hypotension. Structured GlobalRPh route snapshot
      Source IDH51-7ED920CC1F36AD668195D081
      Official access mode
      search
      Source IDH51-BE8FC099347C7E0E73FEDAD9
      Official search query
      Thiamine
      Source IDH51-A6D7AF1F82F1227D7D4E94EC
      Official access reason
      A source-backed DailyMed search is available; select and confirm the exact IV product.
      Source IDH51-F349912AA057C52F085A91BF

      No separate structured rows were bundled for preparation, continuous infusion, dialysis, CRRT. Historical article content and source links may cover these topics.

      Historical IV-push guidance

      Recovered v5.1 source content; historical, awaiting current review.

      PopulationDose scopeConcentrationRateStatusNotes
      Source IDH51-196E0B94B4ED93C6F1CE3C95
      Adult / Pediatric
      Source IDH51-F7DE6D2E70939978A8AC7069
      Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation
      Source IDH51-A8444A3B8DBFD16E09B8E816
      100 mg/mL; dilute for high-dose therapy
      Source IDH51-450134D373ADF7AE14611671
      Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes
      Source IDH51-4D2778F4A5FF54F0AE32906B
      Use only when ordered and supported by current labeling or institutional policy
      Source IDH51-3F8FC44C0837E7542599D008
      Give before or with glucose when deficiency is suspected, but do not delay emergency glucose for hypoglycemia.
      Source IDH51-1EFF78F517BC7C6D477F1F8E

      Historical indication and population dosing

      Recovered tables and source-separated snapshots; full clinical revalidation remains pending.

      Existing dose and route snapshots

      RoutePopulationIndicationDoseIntervalDurationAdministrationSource levelNotes
      Source IDH51-A3327F1F6D84CEF575CCD97F
      IV push
      Source IDH51-06016E915D1013191F85AFC6
      Adult / Pediatric
      Source IDH51-176FF0368447E1502A72FACA
      Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation
      Source IDH51-80F6669E2C9ED437E49AF21E
      Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation
      Source IDH51-D27F5C97380396E503D547A5
      Patient- and indication-specific
      Source IDH51-C5ABDBB642133577B41B8DF8
      See current package insert
      Source IDH51-4684F07EF389831487073228
      Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes
      Source IDH51-2B72B5110C1CA9F98742F629
      Existing GlobalRPh IV push snapshot
      Source IDH51-D6CB5DD4C61F7406F16E2ECB
      Use only when ordered and supported by current labeling or institutional policy Give before or with glucose when deficiency is suspected, but do not delay emergency glucose for hypoglycemia.
      Source IDH51-2C4CF840446D9FF1D03D5457

      Historical renal-function guidance

      Recovered v5.1 source content; historical, awaiting current review.

      Separate renal reference: Open Renal Dosing Master (opens in a new tab)
      Classification
      current_label_review_required
      Source IDH51-87986A870EA37A8A3155520A
      Summary
      Renal dosing status has not been locally normalized; use the current package insert before ordering or administration.
      Source IDH51-4A6F26313DA92FCE525A50A1
      Method note
      Use the renal function estimate and body-size convention specified by the selected label or institutional protocol. Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source.
      Source IDH51-A01F877A9E8A2DF6B0E343C9

      Historical Common IV uses

      Recovered v5.1 source content; historical, awaiting current review.

      1. Suspected Wernicke encephalopathy
        Source IDH51-3A7FD12341AB26DC1D26E21A
      2. Thiamine deficiency
        Source IDH51-BD92C0491F1060A7427E26FA
      3. Refeeding-risk support
        Source IDH51-23249CBAC7BA435AEBE4D2E1

      Historical Warnings and safeguards

      Recovered v5.1 source content; historical, awaiting current review.

      1. Rare anaphylaxis and hypotension.
        Source IDH51-EC65E7439A37820D5344CC56

      Historical Monitoring

      Recovered v5.1 source content; historical, awaiting current review.

      1. Clinical neurologic response
        Source IDH51-D846F6C99E0C3FBCEB6D3B62
      2. Infusion reaction
        Source IDH51-DDD390110942A15FD9C8ABB4
      Other recovered source fields and original editorial metadata

      Original status words such as current, verified, or normalized describe the historical source release. They do not change the clinical review status of this release.

      Catalog source fields

      Id
      thiamine
      Source IDH51-7087CC42D8A979D42E9D792D
      Generic name
      Thiamine
      Source IDH51-B8F5903EA7F3F7C13388F621
      Class
      Toxicology and reversal
      Source IDH51-8EA0D129EB42B76F616C36FC
      Subclass
      Vitamin
      Source IDH51-CE56F3A520B60268189B0C1D
      Summary
      Parenteral thiamine should be administered slowly because rare anaphylaxis and infusion reactions can occur.
      Source IDH51-898874A58BF776F8CFF18D55
      Populations
      1. Adult
        Source IDH51-D7E8CF435FC1797B5EC75AA8
      2. Pediatric
        Source IDH51-1D8D085FD70C091C13E51937
      Evidence tier
      IV push safety normalization - verify stocked product
      Source IDH51-DA420A09C42A0C9A3945E59B
      High alert
      true
      Source IDH51-77DB2F4A9328715D272678F7
      Hazardous
      false
      Source IDH51-312F8EC3106AE6747D3C685D
      Status
      Active
      Source IDH51-DFEB3239C22A809C778AF72C
      Reviewed
      2026-08-29
      Source IDH51-4EE31944893AC0C1E6AA920C
      Version added
      1.2
      Source IDH51-CBC44543453988FAB32CAB83
      Sources
      LabelUrlKind
      Source IDH51-7BD0C4CAEC5A021056D242AC
      DailyMed label search
      Source IDH51-CAC20F2B851F4DDA6405BEC9
      https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Thiamine (opens in a new tab)
      Source IDH51-B8E3CE5520E0B05C40D7B15D
      Primary
      Source IDH51-617521E31240D3D54857C170
      Source IDH51-78126FF7D4D0D235D8371A5B
      GlobalRPh legacy IV dilution monograph
      Source IDH51-E3731BDB7A2EA358BF9C0AFA
      legacy:auto
      Source IDH51-F13E9C6423EACE25233176D7
      Legacy
      Source IDH51-427A3287D7D373AF5E9FB11F
      Legacy title
      Thiamine
      Source IDH51-DC9AB41C9C541E06665D7EF0
      Clinical release verification
      Audit version
      3.4
      Source IDH51-FB635E75DB50A840F6C41FBC
      Audited on
      2026-08-30
      Source IDH51-B77DFC82A8FBBD657A5F5565
      Level
      amber
      Source IDH51-AC1DDC18874A8BD69E17765A
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-942AAE797EAACEDB6D77F1C4
      Exact current label candidate
      false
      Source IDH51-1DB697A3007523E2BE3D117F
      Numeric support ratio
      0
      Source IDH51-754A8B3B6AC1D713D9867944
      Reference url count
      1
      Source IDH51-2DF7FCF571EE12A616F07439
      Broken reference count
      0
      Source IDH51-BD893D26B920E1293CD11701
      Point of use confirmation required
      true
      Source IDH51-EE1A618548831ABB9C1F995D
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-80C22AA763688BD87640B284
      Dailymed search url
      https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Thiamine (opens in a new tab)
      Source IDH51-F2134ADE6A3D673C73075218

      Dosing source fields

      Id
      thiamine
      Source IDH51-0C1282F2AE1766BC20694292
      Generic name
      Thiamine
      Source IDH51-B83E82ADAF5723747E62CBB5
      Coverage status
      direct_official_label_access_plus_local_snapshot
      Source IDH51-B18ADF15DD3301FDC9885484
      Package insert
      Query name
      Thiamine
      Source IDH51-0D66EA4BD7CC2309858F8280
      Product and route must match
      true
      Source IDH51-CDEC04ED0A6CE9BF846EB2F9
      Live current label enabled
      false
      Source IDH51-09FE9951F54870710F0BD78F
      Source priority
      Reviewed local summary when available, then a verified DailyMed label or product search when available, followed by professional references and institutional policy.
      Source IDH51-D789F4BE793E3762DC219845
      Direct official label access enabled
      true
      Source IDH51-19B609A2883F02A91A205DFC
      Outbound server request required
      false
      Source IDH51-799B17E4B5AF86DF2280DE7E
      Local summary status
      not_bundled
      Source IDH51-A185ECE7CD959E7BFC3D5447
      Clinical review
      Locally normalized
      false
      Source IDH51-81F218A92A119FD7326A355A
      Reviewed
      2026-08-29
      Source IDH51-1D1CCA09A4AFFACAB9385B0A
      Status
      Direct official package-insert access enabled; indication-specific local normalization pending.
      Source IDH51-6D3C970BDF5BCE08BCB58DB9
      Clinical release verification
      Audit version
      3.4
      Source IDH51-3BA7F024497219E6C58F4800
      Audited on
      2026-08-30
      Source IDH51-9630C06F3270C8EAB74B60B8
      Level
      amber
      Source IDH51-717F743FF80FA039AB59B5EE
      Release gate
      trusted_professional_source_present_exact_label_unconfirmed
      Source IDH51-6B0E61A7C938F61FBB3D62AF
      Exact current label candidate
      false
      Source IDH51-C647D431B2AFFA51CA06A683
      Numeric support ratio
      0
      Source IDH51-5DBE40BDBEF2470A61789DDE
      Reference url count
      1
      Source IDH51-84F875F28F09512557681395
      Broken reference count
      0
      Source IDH51-A0CF20407E76081392B3C65B
      Point of use confirmation required
      true
      Source IDH51-F85B2DF80ABC3F3239AFE98B
      Note
      Do not treat this record as a fully current product-specific monograph until the exact IV formulation and current sources are confirmed.
      Source IDH51-3DE4226F84ACF2BBD589A11E
      Dailymed search url
      https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Thiamine (opens in a new tab)
      Source IDH51-A65F9F447D16632494C5BCE3
      Historical preparation assessment

      Recovered v5.1 source content; historical, awaiting current review.

      Id
      thiamine
      Source IDH51-E707CDDFA29956C934CB11F6
      Name
      Thiamine
      Source IDH51-00C0793BEAD2E35A564B1408
      Therapeutic class
      Toxicology and reversal
      Source IDH51-73046CDF84C51D84722E7946
      Review version
      3.1
      Source IDH51-A9A3723135CFDDC718E6ACF4
      Review date
      2026-08-30
      Source IDH51-A59FF381016F378AE7836036
      Release status
      no_released_dilution_current_label_review_required
      Source IDH51-ED893AE4E8065427B77BE6E6
      Market status
      Status
      no_current_us_iv_spl_confirmed
      Source IDH51-3873DF083DAD56CCA328E8FC
      Basis
      No high-confidence current IV SPL was automatically selected; legacy information is segregated
      Source IDH51-769F17FE0A7F5E0FEE8C45B8
      Ten point assessment
      Exact formulation
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-FA5F552F97BEF5F85A03B0D6
      Reconstitution concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-2CDAE94B8EA7764D69C8736D
      Maximum or recommended final concentration
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-7D60CAA6324CFA15250ED0F9
      Appropriate standardized containers
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-5668ED66E5A8A5475973C72E
      Adult dosing range
      Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation Dose varies widely by indication; Wernicke protocols use substantially higher doses than routine supplementation
      Source IDH51-928FC204A39D265FBB436F11
      Pediatric dosing range
      Separate renal reference: Open Renal Dosing Master (opens in a new tab)Do not interchange Cockcroft-Gault CrCl, indexed eGFR, and de-indexed eGFR without confirming the dosing source. | existing_route_snapshots: route: IV push | population: Adult / Pediatric | indication: Dose varies widely by indication;
      Source IDH51-A2E99B3B56BE8FB041E2FAB3
      Neonatal dosing range
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-ED9A9B176DBE5B51B3AE68BC
      Infusion time
      Slow IV over at least 5 minutes for small doses; high doses commonly diluted and infused over 30 minutes
      Source IDH51-860A0B027913F798DA38F714
      Fluid restriction alternatives
      Not established in the currently normalized record. Use the current-label panel before clinical use.
      Source IDH51-309106CEBAB9DA4322460C14
      Current manufacturer labeling
      Match confidence
      unresolved
      Source IDH51-30AD3172C52483489C0BD102
      Field provenance
      Exact formulation
      Primary
      not_found
      Source IDH51-7377E33F2414F301C416B9AD
      Reconstitution concentration
      Primary
      not_found
      Source IDH51-F89220A22D352F1FFCADED56
      Maximum or recommended final concentration
      Primary
      not_found
      Source IDH51-7437F72C341665AE082E05F7
      Appropriate standardized containers
      Primary
      not_found
      Source IDH51-DC638E53434AB4337E7E67F8
      Adult dosing range
      Primary
      existing_structured_record
      Source IDH51-F6FDBC8334486C8C28BC87E1
      Pediatric dosing range
      Primary
      existing_record_text
      Source IDH51-8DF568FBB594E1BE50182364
      Neonatal dosing range
      Primary
      not_found
      Source IDH51-1DAEF32B7B09AE79EB6B2A5F
      Infusion time
      Primary
      existing_structured_record
      Source IDH51-89BBA451CFC46BFF73901271
      Fluid restriction alternatives
      Primary
      not_found
      Source IDH51-D34FA45133B7DF447389CEBF
      Current manufacturer labeling
      Primary
      DailyMed search gateway
      Source IDH51-16004A5298764A500B5FF696
      Population applicability
      Adult
      Applicability
      supported_or_source_present
      Source IDH51-33C850321F38CD34088985C1
      Guide generation allowed
      true
      Source IDH51-2E49D368B9E19F63381E72ED
      Pediatric
      Applicability
      supported_or_source_present
      Source IDH51-35AC68146B7FA9E2A6CEB383
      Guide generation allowed
      false
      Source IDH51-848340042DCE59288D3D95F0
      Neonatal
      Applicability
      not_established
      Source IDH51-2646F96ABA5F123F8388A865
      Guide generation allowed
      false
      Source IDH51-1E20369CC22FB70A0E1D3EF2
      Route presence
      Structured dilution
      false
      Source IDH51-D312EEDB319F526C4FCF41FD
      Iv push
      true
      Source IDH51-111E660437CCE5D1F43A5AEC
      Continuous infusion
      false
      Source IDH51-D62A03E5F151FE2FFEE550DD
      Pediatric source
      true
      Source IDH51-9BAF5E16005B4E2E98E9CDCE
      Neonatal source
      false
      Source IDH51-1581D37A9812155F2D95C604
      Legacy reference
      Status
      not_available
      Source IDH51-ED5F8EA890696AD3D72BC132
      Label resolution
      Status
      build_environment_network_unavailable
      Source IDH51-89591F92EF3D97091384B8D2
      Source files
      1. catalog.json
        Source IDH51-E67C5D12E8AE2A2F8174F6E9
      2. dosing.json
        Source IDH51-3FC97033CC2D69EE7EF85BA8
      3. legacy-map.json
        Source IDH51-F267FF30CCC6834D874EFB41
      4. new-in-v1.2.json
        Source IDH51-DEE286C71FD6115DE9E24B0C
      Clinical release note
      Preparation instructions are released only at the evidence level shown. Legacy content remains visibly separate. Exact product, NDC, route, current labeling, and institutional policy must be confirmed.
      Source IDH51-503662EF9C5D4549DF0245FE
      Historical statement IDs and source locations

      These IDs identify recovered source units. They are not evidence-qualified clinical claims.

      Historical IDOriginal source locationStatus
      H51-7087CC42D8A979D42E9D792Dcatalog.json
      /records/236/id
      Historical; current review incomplete
      H51-B8F5903EA7F3F7C13388F621catalog.json
      /records/236/generic_name
      Historical; current review incomplete
      H51-8EA0D129EB42B76F616C36FCcatalog.json
      /records/236/class
      Historical; current review incomplete
      H51-CE56F3A520B60268189B0C1Dcatalog.json
      /records/236/subclass
      Historical; current review incomplete
      H51-898874A58BF776F8CFF18D55catalog.json
      /records/236/summary
      Historical; current review incomplete
      H51-3A7FD12341AB26DC1D26E21Acatalog.json
      /records/236/common_uses/0
      Historical; current review incomplete
      H51-BD92C0491F1060A7427E26FAcatalog.json
      /records/236/common_uses/1
      Historical; current review incomplete
      H51-23249CBAC7BA435AEBE4D2E1catalog.json
      /records/236/common_uses/2
      Historical; current review incomplete
      H51-196E0B94B4ED93C6F1CE3C95catalog.json
      /records/236/iv_push/0
      Historical; current review incomplete
      H51-F7DE6D2E70939978A8AC7069catalog.json
      /records/236/iv_push/0/population
      Historical; current review incomplete
      H51-A8444A3B8DBFD16E09B8E816catalog.json
      /records/236/iv_push/0/dose_scope
      Historical; current review incomplete
      H51-450134D373ADF7AE14611671catalog.json
      /records/236/iv_push/0/concentration
      Historical; current review incomplete
      H51-4D2778F4A5FF54F0AE32906Bcatalog.json
      /records/236/iv_push/0/rate
      Historical; current review incomplete
      H51-3F8FC44C0837E7542599D008catalog.json
      /records/236/iv_push/0/status
      Historical; current review incomplete
      H51-1EFF78F517BC7C6D477F1F8Ecatalog.json
      /records/236/iv_push/0/notes
      Historical; current review incomplete
      H51-EC65E7439A37820D5344CC56catalog.json
      /records/236/warnings/0
      Historical; current review incomplete
      H51-D846F6C99E0C3FBCEB6D3B62catalog.json
      /records/236/monitoring/0
      Historical; current review incomplete
      H51-DDD390110942A15FD9C8ABB4catalog.json
      /records/236/monitoring/1
      Historical; current review incomplete
      H51-D7E8CF435FC1797B5EC75AA8catalog.json
      /records/236/populations/0
      Historical; current review incomplete
      H51-1D8D085FD70C091C13E51937catalog.json
      /records/236/populations/1
      Historical; current review incomplete
      H51-DA420A09C42A0C9A3945E59Bcatalog.json
      /records/236/evidence_tier
      Historical; current review incomplete
      H51-77DB2F4A9328715D272678F7catalog.json
      /records/236/high_alert
      Historical; current review incomplete
      H51-312F8EC3106AE6747D3C685Dcatalog.json
      /records/236/hazardous
      Historical; current review incomplete
      H51-DFEB3239C22A809C778AF72Ccatalog.json
      /records/236/status
      Historical; current review incomplete
      H51-4EE31944893AC0C1E6AA920Ccatalog.json
      /records/236/reviewed
      Historical; current review incomplete
      H51-CBC44543453988FAB32CAB83catalog.json
      /records/236/version_added
      Historical; current review incomplete
      H51-7BD0C4CAEC5A021056D242ACcatalog.json
      /records/236/sources/0
      Historical; current review incomplete
      H51-CAC20F2B851F4DDA6405BEC9catalog.json
      /records/236/sources/0/label
      Historical; current review incomplete
      H51-B8E3CE5520E0B05C40D7B15Dcatalog.json
      /records/236/sources/0/url
      Historical; current review incomplete
      H51-617521E31240D3D54857C170catalog.json
      /records/236/sources/0/kind
      Historical; current review incomplete
      H51-78126FF7D4D0D235D8371A5Bcatalog.json
      /records/236/sources/1
      Historical; current review incomplete
      H51-E3731BDB7A2EA358BF9C0AFAcatalog.json
      /records/236/sources/1/label
      Historical; current review incomplete
      H51-F13E9C6423EACE25233176D7catalog.json
      /records/236/sources/1/url
      Historical; current review incomplete
      H51-427A3287D7D373AF5E9FB11Fcatalog.json
      /records/236/sources/1/kind
      Historical; current review incomplete
      H51-DC9AB41C9C541E06665D7EF0catalog.json
      /records/236/legacy_title
      Historical; current review incomplete
      H51-FB635E75DB50A840F6C41FBCcatalog.json
      /records/236/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-B77DFC82A8FBBD657A5F5565catalog.json
      /records/236/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-AC1DDC18874A8BD69E17765Acatalog.json
      /records/236/clinical_release_verification/level
      Historical; current review incomplete
      H51-942AAE797EAACEDB6D77F1C4catalog.json
      /records/236/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-1DB697A3007523E2BE3D117Fcatalog.json
      /records/236/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-B8809A15A0735C54F495DCF9catalog.json
      /records/236/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-41BE87209D04434679090851catalog.json
      /records/236/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-754A8B3B6AC1D713D9867944catalog.json
      /records/236/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-2DF7FCF571EE12A616F07439catalog.json
      /records/236/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-BD893D26B920E1293CD11701catalog.json
      /records/236/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-EE1A618548831ABB9C1F995Dcatalog.json
      /records/236/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-80C22AA763688BD87640B284catalog.json
      /records/236/clinical_release_verification/note
      Historical; current review incomplete
      H51-F2134ADE6A3D673C73075218catalog.json
      /records/236/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-0C1282F2AE1766BC20694292dosing.json
      /records/236/id
      Historical; current review incomplete
      H51-B83E82ADAF5723747E62CBB5dosing.json
      /records/236/generic_name
      Historical; current review incomplete
      H51-B18ADF15DD3301FDC9885484dosing.json
      /records/236/coverage_status
      Historical; current review incomplete
      H51-0D66EA4BD7CC2309858F8280dosing.json
      /records/236/package_insert/query_name
      Historical; current review incomplete
      H51-6539BE456DF06EB3704D5623dosing.json
      /records/236/package_insert/preferred_setid
      Historical; current review incomplete
      H51-CDEC04ED0A6CE9BF846EB2F9dosing.json
      /records/236/package_insert/product_and_route_must_match
      Historical; current review incomplete
      H51-09FE9951F54870710F0BD78Fdosing.json
      /records/236/package_insert/live_current_label_enabled
      Historical; current review incomplete
      H51-D789F4BE793E3762DC219845dosing.json
      /records/236/package_insert/source_priority
      Historical; current review incomplete
      H51-19B609A2883F02A91A205DFCdosing.json
      /records/236/package_insert/direct_official_label_access_enabled
      Historical; current review incomplete
      H51-799B17E4B5AF86DF2280DE7Edosing.json
      /records/236/package_insert/outbound_server_request_required
      Historical; current review incomplete
      H51-A185ECE7CD959E7BFC3D5447dosing.json
      /records/236/package_insert/local_summary_status
      Historical; current review incomplete
      H51-87986A870EA37A8A3155520Adosing.json
      /records/236/renal/classification
      Historical; current review incomplete
      H51-4A6F26313DA92FCE525A50A1dosing.json
      /records/236/renal/summary
      Historical; current review incomplete
      H51-A01F877A9E8A2DF6B0E343C9dosing.json
      /records/236/renal/method_note
      Historical; current review incomplete
      H51-A3327F1F6D84CEF575CCD97Fdosing.json
      /records/236/existing_route_snapshots/0
      Historical; current review incomplete
      H51-06016E915D1013191F85AFC6dosing.json
      /records/236/existing_route_snapshots/0/route
      Historical; current review incomplete
      H51-176FF0368447E1502A72FACAdosing.json
      /records/236/existing_route_snapshots/0/population
      Historical; current review incomplete
      H51-80F6669E2C9ED437E49AF21Edosing.json
      /records/236/existing_route_snapshots/0/indication
      Historical; current review incomplete
      H51-D27F5C97380396E503D547A5dosing.json
      /records/236/existing_route_snapshots/0/dose
      Historical; current review incomplete
      H51-C5ABDBB642133577B41B8DF8dosing.json
      /records/236/existing_route_snapshots/0/interval
      Historical; current review incomplete
      H51-4684F07EF389831487073228dosing.json
      /records/236/existing_route_snapshots/0/duration
      Historical; current review incomplete
      H51-2B72B5110C1CA9F98742F629dosing.json
      /records/236/existing_route_snapshots/0/administration
      Historical; current review incomplete
      H51-D6CB5DD4C61F7406F16E2ECBdosing.json
      /records/236/existing_route_snapshots/0/source_level
      Historical; current review incomplete
      H51-2C4CF840446D9FF1D03D5457dosing.json
      /records/236/existing_route_snapshots/0/notes
      Historical; current review incomplete
      H51-81F218A92A119FD7326A355Adosing.json
      /records/236/clinical_review/locally_normalized
      Historical; current review incomplete
      H51-1D1CCA09A4AFFACAB9385B0Adosing.json
      /records/236/clinical_review/reviewed
      Historical; current review incomplete
      H51-6D3C970BDF5BCE08BCB58DB9dosing.json
      /records/236/clinical_review/status
      Historical; current review incomplete
      H51-3BA7F024497219E6C58F4800dosing.json
      /records/236/clinical_release_verification/audit_version
      Historical; current review incomplete
      H51-9630C06F3270C8EAB74B60B8dosing.json
      /records/236/clinical_release_verification/audited_on
      Historical; current review incomplete
      H51-717F743FF80FA039AB59B5EEdosing.json
      /records/236/clinical_release_verification/level
      Historical; current review incomplete
      H51-6B0E61A7C938F61FBB3D62AFdosing.json
      /records/236/clinical_release_verification/release_gate
      Historical; current review incomplete
      H51-C647D431B2AFFA51CA06A683dosing.json
      /records/236/clinical_release_verification/exact_current_label_candidate
      Historical; current review incomplete
      H51-4AA178B32A8637B55B41EB36dosing.json
      /records/236/clinical_release_verification/selected_setid
      Historical; current review incomplete
      H51-0EEDCB3921E2C6E1151A0E29dosing.json
      /records/236/clinical_release_verification/selected_label_title
      Historical; current review incomplete
      H51-5DBE40BDBEF2470A61789DDEdosing.json
      /records/236/clinical_release_verification/numeric_support_ratio
      Historical; current review incomplete
      H51-84F875F28F09512557681395dosing.json
      /records/236/clinical_release_verification/reference_url_count
      Historical; current review incomplete
      H51-A0CF20407E76081392B3C65Bdosing.json
      /records/236/clinical_release_verification/broken_reference_count
      Historical; current review incomplete
      H51-F85B2DF80ABC3F3239AFE98Bdosing.json
      /records/236/clinical_release_verification/point_of_use_confirmation_required
      Historical; current review incomplete
      H51-3DE4226F84ACF2BBD589A11Edosing.json
      /records/236/clinical_release_verification/note
      Historical; current review incomplete
      H51-A65F9F447D16632494C5BCE3dosing.json
      /records/236/clinical_release_verification/dailymed_search_url
      Historical; current review incomplete
      H51-8166A253FAF0620DEA076248first-look-v5.1.json
      /records/236/id
      Historical; current review incomplete
      H51-C692A08A06CD38DA8B02B3CEfirst-look-v5.1.json
      /records/236/generic_name
      Historical; current review incomplete
      H51-C2071EA8997168D530736CA3first-look-v5.1.json
      /records/236/class
      Historical; current review incomplete
      H51-5FA9C4C6EFFDE10BC2B088F2first-look-v5.1.json
      /records/236/subclass
      Historical; current review incomplete
      H51-B8EB988511761E1C6FEC9F86first-look-v5.1.json
      /records/236/primary_uses/0
      Historical; current review incomplete
      H51-57ECC252549A0894D66D6B96first-look-v5.1.json
      /records/236/primary_uses/1
      Historical; current review incomplete
      H51-17B7EE7CBD901C652486B618first-look-v5.1.json
      /records/236/primary_uses/2
      Historical; current review incomplete
      H51-9E031FDBD25F209C1D7DAB03first-look-v5.1.json
      /records/236/mechanism
      Historical; current review incomplete
      H51-BF7FB169DFDEDE01098CE710first-look-v5.1.json
      /records/236/mechanism_level
      Historical; current review incomplete
      H51-94473BF6E50647D829EA5210first-look-v5.1.json
      /records/236/basic_dosing_orientation
      Historical; current review incomplete
      H51-20D3AA8CE316B101656E1C0Dfirst-look-v5.1.json
      /records/236/administration_orientation
      Historical; current review incomplete
      H51-FDB471785AE6A34B49F0BD9Ffirst-look-v5.1.json
      /records/236/renal_and_population_orientation
      Historical; current review incomplete
      H51-82657F6F158EA0CCD79FB7FEfirst-look-v5.1.json
      /records/236/key_safety_orientation/0
      Historical; current review incomplete
      H51-943BADBE5714304583F0E734first-look-v5.1.json
      /records/236/coverage_path
      Historical; current review incomplete
      H51-26B5C78ED58699B73A5F55ADfirst-look-v5.1.json
      /records/236/coverage_path_label
      Historical; current review incomplete
      H51-98AB0AEB50B786D9001D8AE2first-look-v5.1.json
      /records/236/official_label_url
      Historical; current review incomplete
      H51-D0ABC342C9F73568BED848A2first-look-v5.1.json
      /records/236/legacy_title
      Historical; current review incomplete
      H51-F037ABAD4E883DCC6756EF4Cfirst-look-v5.1.json
      /records/236/review_note
      Historical; current review incomplete
      H51-7ED920CC1F36AD668195D081first-look-v5.1.json
      /records/236/search_text
      Historical; current review incomplete
      H51-6BCF3F4D7765E687506A0952first-look-v5.1.json
      /records/236/official_search_url
      Historical; current review incomplete
      H51-BE8FC099347C7E0E73FEDAD9first-look-v5.1.json
      /records/236/official_access_mode
      Historical; current review incomplete
      H51-758CE5072A75DF7D2D187E49first-look-v5.1.json
      /records/236/official_access_url
      Historical; current review incomplete
      H51-A6D7AF1F82F1227D7D4E94ECfirst-look-v5.1.json
      /records/236/official_search_query
      Historical; current review incomplete
      H51-F349912AA057C52F085A91BFfirst-look-v5.1.json
      /records/236/official_access_reason
      Historical; current review incomplete
      H51-E707CDDFA29956C934CB11F6preparation-assessments-v3.8.json
      /236/id
      Historical; current review incomplete
      H51-00C0793BEAD2E35A564B1408preparation-assessments-v3.8.json
      /236/name
      Historical; current review incomplete
      H51-AF0F702D864DC589AF7DF5BEpreparation-assessments-v3.8.json
      /236/brands
      Historical; current review incomplete
      H51-73046CDF84C51D84722E7946preparation-assessments-v3.8.json
      /236/therapeutic_class
      Historical; current review incomplete
      H51-A9A3723135CFDDC718E6ACF4preparation-assessments-v3.8.json
      /236/review_version
      Historical; current review incomplete
      H51-A59FF381016F378AE7836036preparation-assessments-v3.8.json
      /236/review_date
      Historical; current review incomplete
      H51-ED893AE4E8065427B77BE6E6preparation-assessments-v3.8.json
      /236/release_status
      Historical; current review incomplete
      H51-3873DF083DAD56CCA328E8FCpreparation-assessments-v3.8.json
      /236/market_status/status
      Historical; current review incomplete
      H51-769F17FE0A7F5E0FEE8C45B8preparation-assessments-v3.8.json
      /236/market_status/basis
      Historical; current review incomplete
      H51-FA5F552F97BEF5F85A03B0D6preparation-assessments-v3.8.json
      /236/ten_point_assessment/exact_formulation
      Historical; current review incomplete
      H51-2CDAE94B8EA7764D69C8736Dpreparation-assessments-v3.8.json
      /236/ten_point_assessment/reconstitution_concentration
      Historical; current review incomplete
      H51-7D60CAA6324CFA15250ED0F9preparation-assessments-v3.8.json
      /236/ten_point_assessment/maximum_or_recommended_final_concentration
      Historical; current review incomplete
      H51-5668ED66E5A8A5475973C72Epreparation-assessments-v3.8.json
      /236/ten_point_assessment/appropriate_standardized_containers
      Historical; current review incomplete
      H51-928FC204A39D265FBB436F11preparation-assessments-v3.8.json
      /236/ten_point_assessment/adult_dosing_range
      Historical; current review incomplete
      H51-A2E99B3B56BE8FB041E2FAB3preparation-assessments-v3.8.json
      /236/ten_point_assessment/pediatric_dosing_range
      Historical; current review incomplete
      H51-ED9A9B176DBE5B51B3AE68BCpreparation-assessments-v3.8.json
      /236/ten_point_assessment/neonatal_dosing_range
      Historical; current review incomplete
      H51-860A0B027913F798DA38F714preparation-assessments-v3.8.json
      /236/ten_point_assessment/infusion_time
      Historical; current review incomplete
      H51-309106CEBAB9DA4322460C14preparation-assessments-v3.8.json
      /236/ten_point_assessment/fluid_restriction_alternatives
      Historical; current review incomplete
      H51-989B8578CE893AD55BA3DBCDpreparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/setid
      Historical; current review incomplete
      H51-3899B73AD2FF02FF40E4F8E2preparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/title
      Historical; current review incomplete
      H51-987281B1BE8735A562554627preparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/published_date
      Historical; current review incomplete
      H51-3C5EAA30EB1CE85775DCC09Bpreparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/manufacturer
      Historical; current review incomplete
      H51-30AD3172C52483489C0BD102preparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/match_confidence
      Historical; current review incomplete
      H51-F5CE5482F0153FCAB6D9D145preparation-assessments-v3.8.json
      /236/ten_point_assessment/current_manufacturer_labeling/url
      Historical; current review incomplete
      H51-7377E33F2414F301C416B9ADpreparation-assessments-v3.8.json
      /236/field_provenance/exact_formulation/primary
      Historical; current review incomplete
      H51-F89220A22D352F1FFCADED56preparation-assessments-v3.8.json
      /236/field_provenance/reconstitution_concentration/primary
      Historical; current review incomplete
      H51-7437F72C341665AE082E05F7preparation-assessments-v3.8.json
      /236/field_provenance/maximum_or_recommended_final_concentration/primary
      Historical; current review incomplete
      H51-DC638E53434AB4337E7E67F8preparation-assessments-v3.8.json
      /236/field_provenance/appropriate_standardized_containers/primary
      Historical; current review incomplete
      H51-F6FDBC8334486C8C28BC87E1preparation-assessments-v3.8.json
      /236/field_provenance/adult_dosing_range/primary
      Historical; current review incomplete
      H51-8DF568FBB594E1BE50182364preparation-assessments-v3.8.json
      /236/field_provenance/pediatric_dosing_range/primary
      Historical; current review incomplete
      H51-1DAEF32B7B09AE79EB6B2A5Fpreparation-assessments-v3.8.json
      /236/field_provenance/neonatal_dosing_range/primary
      Historical; current review incomplete
      H51-89BBA451CFC46BFF73901271preparation-assessments-v3.8.json
      /236/field_provenance/infusion_time/primary
      Historical; current review incomplete
      H51-D34FA45133B7DF447389CEBFpreparation-assessments-v3.8.json
      /236/field_provenance/fluid_restriction_alternatives/primary
      Historical; current review incomplete
      H51-16004A5298764A500B5FF696preparation-assessments-v3.8.json
      /236/field_provenance/current_manufacturer_labeling/primary
      Historical; current review incomplete
      H51-33C850321F38CD34088985C1preparation-assessments-v3.8.json
      /236/population_applicability/adult/applicability
      Historical; current review incomplete
      H51-2E49D368B9E19F63381E72EDpreparation-assessments-v3.8.json
      /236/population_applicability/adult/guide_generation_allowed
      Historical; current review incomplete
      H51-35AC68146B7FA9E2A6CEB383preparation-assessments-v3.8.json
      /236/population_applicability/pediatric/applicability
      Historical; current review incomplete
      H51-848340042DCE59288D3D95F0preparation-assessments-v3.8.json
      /236/population_applicability/pediatric/guide_generation_allowed
      Historical; current review incomplete
      H51-2646F96ABA5F123F8388A865preparation-assessments-v3.8.json
      /236/population_applicability/neonatal/applicability
      Historical; current review incomplete
      H51-1E20369CC22FB70A0E1D3EF2preparation-assessments-v3.8.json
      /236/population_applicability/neonatal/guide_generation_allowed
      Historical; current review incomplete
      H51-D312EEDB319F526C4FCF41FDpreparation-assessments-v3.8.json
      /236/route_presence/structured_dilution
      Historical; current review incomplete
      H51-111E660437CCE5D1F43A5AECpreparation-assessments-v3.8.json
      /236/route_presence/iv_push
      Historical; current review incomplete
      H51-D62A03E5F151FE2FFEE550DDpreparation-assessments-v3.8.json
      /236/route_presence/continuous_infusion
      Historical; current review incomplete
      H51-9BAF5E16005B4E2E98E9CDCEpreparation-assessments-v3.8.json
      /236/route_presence/pediatric_source
      Historical; current review incomplete
      H51-1581D37A9812155F2D95C604preparation-assessments-v3.8.json
      /236/route_presence/neonatal_source
      Historical; current review incomplete
      H51-ED5F8EA890696AD3D72BC132preparation-assessments-v3.8.json
      /236/legacy_reference/status
      Historical; current review incomplete
      H51-89591F92EF3D97091384B8D2preparation-assessments-v3.8.json
      /236/label_resolution/status
      Historical; current review incomplete
      H51-E67C5D12E8AE2A2F8174F6E9preparation-assessments-v3.8.json
      /236/source_files/0
      Historical; current review incomplete
      H51-3FC97033CC2D69EE7EF85BA8preparation-assessments-v3.8.json
      /236/source_files/1
      Historical; current review incomplete
      H51-F267FF30CCC6834D874EFB41preparation-assessments-v3.8.json
      /236/source_files/2
      Historical; current review incomplete
      H51-DEE286C71FD6115DE9E24B0Cpreparation-assessments-v3.8.json
      /236/source_files/3
      Historical; current review incomplete
      H51-503662EF9C5D4549DF0245FEpreparation-assessments-v3.8.json
      /236/clinical_release_note
      Historical; current review incomplete